Purdue Pharma L.P.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$67.0M
Doctors Paid
18,457
Transactions
76,141
2024 Total
$2.5M
Payment Breakdown by Category
Research$38.3M (57.2%)
Consulting$24.6M (36.8%)
Food & Beverage$1.1M (1.6%)
Travel$136,774 (0.2%)
Royalty/License$1,200 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $38.3M | 1,615 | 57.2% |
| Consulting Fee | $24.6M | 607 | 36.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.3M | 1,281 | 3.4% |
| Food and Beverage | $1.1M | 71,952 | 1.6% |
| Grant | $497,334 | 21 | 0.7% |
| Travel and Lodging | $136,774 | 634 | 0.2% |
| Honoraria | $21,970 | 2 | 0.0% |
| Charitable Contribution | $14,541 | 6 | 0.0% |
| Education | $11,551 | 7 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $6,890 | 11 | 0.0% |
| Royalty or License | $1,200 | 5 | 0.0% |
Payments by Type
Research
$38.3M
1,615 transactions
General
$28.6M
74,526 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| HVB1001 | $5.9M | 0 | 34 |
| VAN2001 | $3.7M | 0 | 302 |
| NAL1002 | $3.5M | 0 | 20 |
| NAL9001 | $2.8M | 1 | 23 |
| OAG1006 | $2.8M | 0 | 5 |
| OAG1010 | $2.6M | 0 | 7 |
| BOX1001 | $2.5M | 0 | 11 |
| An open-label, multicenter, multiple-dose, safety and tolerability study of Adhansia XR extended-release capsules in children 4 to 12 years of age | $1.6M | 3 | 170 |
| Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States | $1.5M | 15 | 388 |
| 063-015 | $1.5M | 0 | 43 |
| OAG1008 | $943,948 | 0 | 10 |
| A Two-Part Study to Characterize the Pharmacokinetics of Nalmefene Hydrochloride and to Assess the Time Course of Reversal and Breakthrough of Opioid Agonist Effects Following Naloxone and Nalmefene Administration | $919,395 | 0 | 6 |
| PMR 2923-2 study of OxyContin utilization among pediatric patients | $904,535 | 0 | 58 |
| PMR 2923-2 A Nationally Representative Drug Utilization Study of OxyContin in Children Aged 17 Years and Younger | $864,710 | 0 | 11 |
| TKA1005 | $858,990 | 0 | 6 |
| NAL1003 | $748,748 | 0 | 5 |
| 063-020 | $612,232 | 0 | 23 |
| OEB9001 | $576,045 | 0 | 4 |
| Clinical Outcomes from Injectable Nalmefene in the Emergency Department | $478,080 | 0 | 6 |
| Cost and Prevalence of Opioid Abuse | $415,000 | 0 | 3 |
| The Effect of Primary Care Opioid Taper Plans on Sustained Opioid Taper | $361,363 | 0 | 5 |
| OxyContin Utilization in Pediatric Patients: Prescribing Trends from 2011-2018; PMR2923-2 | $342,234 | 0 | 7 |
| ER/LA Opioid PMR -bservational Studies 1A/1B/3A | $301,865 | 0 | 9 |
| TKA2001 | $224,458 | 0 | 136 |
| Neuroimaging Effects of Cognitive Behavioral Therapy in Fibromyalgia | $158,100 | 0 | 4 |
| Alpha as a Predictive Biomarker (APB) | $152,046 | 0 | 2 |
| PMR 3033-11: Study 11 | $131,365 | 10 | 57 |
| Changes in Rates of Opioid Overdose and Poisoning Events in the Kaiser Permanente Health System with the Introduction of Reformulated OxyContin | $110,704 | 0 | 2 |
| 063-017 | $109,216 | 0 | 11 |
| A Pragmatic, Single Arm Trial of Prehospital Nalmefene for Treatment of Opioid Toxicity in a Population with High Fentanyl Use | $105,475 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors — Page 4
| Doctor | Specialty | Location | Total | 2017 |
|---|---|---|---|---|
| Dr. Carl Bazil, M.d, Ph.d, M.D, PH.D | Sleep Medicine | New York, NY | $9,191 | $0 |
| Christoph Hornik, Md, MD | Pediatric Critical Care Medicine | Durham, NC | $8,880 | $0 |
| Dr. Fernando Gerena Nieves, M.d ,D.a.b.a ,F.abpm, M.D ,D.A.B.A ,F.ABPM | Pain Medicine | Catano, PR | $8,639 | $0 |
| James Knutson, M.d, M.D | Prescribing (Medical) | Kirkland, WA | $8,450 | $0 |
| Joseph Shurman, M.d, M.D | Anesthesiology | San Diego, CA | $8,109 | $0 |
| Jerry Twiggs, M.d, M.D | Adolescent Medicine | St. George, UT | $8,075 | $0 |
| Leland Lou, Md, MD | Pain Medicine | Meridian, MS | $7,892 | $0 |
| Dr. Rachel Dew, M.d, M.D | Psychiatry | Durham, NC | $7,864 | $0 |
| Dr. Ahmet Dirican, Md, MD | Geriatric Medicine | New Bedford, MA | $7,788 | $0 |
| Dr. David Miramontes, M.d, M.D | Emergency Medicine | San Antonio, TX | $7,462 | $0 |
| Emma Guttman, Md, MD | Dermatology | New York, NY | $5,898 | $0 |
| Alexander Ford, Md, MD | Cardiovascular Disease | Los Angeles, CA | $5,627 | $0 |
| Vivek Mehta, Md, MD | Anesthesiology | Arlington, TX | $5,468 | $0 |
| Michael Cohen-Wolkowiez, Md, MD | Pediatric Infectious Diseases | Durham, NC | $5,200 | $0 |
| Dr. Bradley Cash, Md,Pmr, MD,PMR | Physical Medicine & Rehabilitation | White Plains, NY | $5,044 | $0 |
| Dr. Andrea Cercek, M.d, M.D | Medical Oncology | New York, NY | $5,031 | $0 |
| Ernest Ast, Md, MD | Dermatology | Jamaica, NY | $4,950 | $0 |
| Dr. Raymond Anton, Md, MD | Addiction Psychiatry | Charleston, SC | $4,895 | $0 |
| John Goldenring, M.d, M.D | Pediatrics | La Mesa, CA | $4,811 | $0 |
| Paul Oberstein, Md, MD | Internal Medicine | New York, NY | $4,603 | $0 |
| Dr. Afsaneh Barzi, M.d, M.D | Internal Medicine | Los Angeles, CA | $4,552 | $0 |
| Bill Mc Carberg, Md, MD | Family Medicine | San Diego, CA | $4,538 | $0 |
| Al Benson, Md, MD | Medical Oncology | Chicago, IL | $4,449 | $0 |
| Olatunji Alese, M.d, M.D | Hematology & Oncology | Atlanta, GA | $4,440 | $0 |
| Dr. Stuart Rosenblum, Md, Phd, MD, PHD | Anesthesiology | Portland, OR | $4,245 | $0 |
Ad
Top Products
- OXYCONTIN $7.8M
- ADHANSIA XR $3.3M
Associated Products (6)
- OXYCONTIN $7.8M
- NALMEFENE HYDROCHLORIDE $1.7M
- HYSINGLA ER $1.2M
- SYMPROIC $1.0M
- Oxycontin $415,000
- BUTRANS $151,810
Payment Categories
- Food & Beverage $1.1M
- Consulting $24.6M
- Travel & Lodging $136,774
- Research $38.3M
- Royalties $1,200
About Purdue Pharma L.P.
Purdue Pharma L.P. has made $67.0M in payments to 18,457 healthcare providers, recorded across 76,141 transactions in the CMS Open Payments database. In 2024, the company paid $2.5M. The top product by payment volume is OXYCONTIN ($7.8M).
Payments were distributed across 167 medical specialties. The top specialty by payment amount is Internal Medicine ($1.1M to 3,460 doctors).
Payment categories include: Food & Beverage ($1.1M), Consulting ($24.6M), Research ($38.3M), Travel & Lodging ($136,774), Royalties ($1,200).
Purdue Pharma L.P. is associated with 6 products in the CMS Open Payments database, including OXYCONTIN, NALMEFENE HYDROCHLORIDE, and HYSINGLA ER.